Startups
EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market CAR-T therapies for the treatment of cancer. Founded in 2015, The company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and across the US with sites in West Palm Beach and San Diego.
Overview
Location
United States, Florida, West Palm Beach
Employees
11-50
Total raised
$19M
Founded date
2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 13, 2020 | 3 things to know in #MiamiTech: $19M funding round, Endeavor ScaleUp opens applications, more | Facebook Tweet Pin LinkedIn Email 1 Exuma Biotech raises $19 million in funding Exuma Biotech, formerly known as F1 Oncology, announced it has raised $19 million in Series B financing. The West Palm Beach-based clinical-stage biotechnology ... |
| Mar 12, 2020 | Exuma Biotech Raises $19M in Series B Financing | Exuma Biotech Corp. (formerly known as F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, raised $19M in Series B financing. Backers included MSD Partners, F1 BioVent... |
| May 22, 2019 | CAR-T therapy for kidney cancer shows early signs of efficacy in Chinese trial | The main difference between the CAR-T’s is that they respectively target the antigens AXL and ROR2, but they were both included in an “umbrella” clinical trial that randomized patients to receive one or the other depending on which antigen ... |
| Feb 19, 2018 | Biotech startup Unleash Immuno Oncolytics raises $3 million to develop the next generation of oncolytic viruses for the treatment of cancer | St. Louis-based Biotech startup, Unleash Immuno Oncolytics, announced today it has raised $3 million investment from publicly-traded Japanese-based Oncolys BioPharma to advance cancer therapies. Founded in 2015, Unleash Immuno Oncolytics de... |
| CAR-T therapy for kidney cancer shows early signs of efficacy in Chinese trial | A Chinese company has presented early clinical data on two CAR-T therapies in patients with kidney cancer, and it plans to decide by the end of the year whether to expand the therapies’ development to Europe or the US. Exuma Biotechnology –... | |
| Exuma Biotech | “EXUMA Biotech is a clinical-stage biotech company advancing gene vector delivery to enhance patient access to innovative cell and gene therapies.” |
Reviews 0
FAQ about EXUMA Biotech
When was EXUMA Biotech founded?
EXUMA Biotech was founded in 2015.
How much funding has EXUMA Biotech raised?
EXUMA Biotech has raised $19M in total across 1 funding round.
What has the press written about EXUMA Biotech?
Parsers VC has collected 7 articles mentioning EXUMA Biotech, among them “3 things to know in #MiamiTech: $19M funding round, Endeavor ScaleUp opens applications, more” (Mar 13, 2020) and “Exuma Biotech Raises $19M in Series B Financing” (Mar 12, 2020).
Is EXUMA Biotech still active?
Yes, EXUMA Biotech is active; its latest activity on Parsers VC dates from Mar 13, 2020.